Quantcast
Last updated on April 24, 2014 at 14:25 EDT

Latest Angiogenesis inhibitor Stories

2013-04-02 12:30:07

DUBLIN, April 2, 2013 /PRNewswire/ -- Research and Markets) has announced the addition of the "Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013" report to their offering      (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is...

2012-04-02 09:14:34

The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. The results also revealed that increases in interleukin-8 levels early after treatment with pazopanib may predict a lack of tumor response to the therapy. "Historically, prognosis of patients with relapsed or refractory urothelial cancer is quite dismal," said Andrea...

2012-03-05 23:13:39

Persistent protein expression may explain why tumors return after therapy in glioblastoma patients, according to a study published on March 5th in the Journal of Experimental Medicine. Current therapy for glioblastoma, the most prevalent malignant brain tumor in adults, includes targeting a protein called VEGF, which promotes the growth of blood vessels to the tumor. Unfortunately, in most glioblastoma patients treated with anti-VEGF drugs, tumors return shortly after treatment. Through...

2012-01-30 06:00:00

MELBOURNE, Australia, Jan. 30, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection. Importantly the data also showed that VEGF-C blockade, through administration of Circadian's lead development candidate VGX-100, a human antibody against VEGF-C,...

2012-01-25 12:38:01

Finding could explain limited success of anti-angiogenesis treatments in breast cancer Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't lead to longer survival, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center. The drugs Avastin and Sutent have been looked at as potential breast cancer...

2012-01-10 21:26:40

Researchers at Linköping University are now launching a plan to effectively treat psoriasis. About 300 000 Swedes suffer from the difficult to treat disease, which manifests itself in scaly and often itchy patches on the skin. The reason is that cells divide without restraint as new blood vessels form in the deeper layers of the skin. An important component is the psoriasin protein (S100A7), which are abundant in psoriasis-affected skin but rarely in normal skin. The same...

2011-11-14 15:21:51

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011. "These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said...

2011-11-14 15:20:53

Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a novel antiangiogenic receptor may help patients whose cancer does not respond to existing agents. The experimental agent, PF-03446962, targets activin...

2011-09-13 08:00:00

MELBOURNE, Australia, Sept. 13, 2011 /PRNewswire/ -- Data published in the scientific journal Archives of Ophthalmology generated by investigators at the Schepens Eye Research Institute led by Harvard University Professor Reza Dana. VGX-100 significantly reduced inflammation and corneal epitheliopathy in a mouse model of Dry Eye Disease. Data indicates major potential opportunity for VGX-100 as a therapeutic for Dry Eye Disease. Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY)...

2011-08-18 12:27:00

CAMBRIDGE, Mass., Aug. 18, 2011 /PRNewswire/ -- Leading angiogenesis and cancer researcher Dr. Robert S. Kerbel of the University of Toronto will deliver the Future of Medicine Keynote Address at the Angiogenesis Foundation's 9th International M. Judah Folkman Conference -- New Frontiers in Therapeutic Development. The conference will take place on October 29-30, 2011 in Cambridge, MA, and attracts key opinion leaders from academia, industry and government to discuss the latest scientific...